Klarity-C was a suitable alternative treatment for patients with dry eye disease, according to a study published in Clinical Ophthalmology.
OSN Cataract Surgery Board Member Cynthia A. Matossian, MD, FACS, told Ocular Surgery News that while therapies such as Restasis (cyclosporine 0.05%, Allergan), Xiidra (lifitegrast 5%, Novartis) and Cequa (cyclosporine 0.09%, Sun Ophthalmics) have been available for many years, some patients do not have access to them.
“We’re fortunate that not only do we have more diagnostic tools to help eye care providers diagnose dry eye, but there’s